Claudin 18.2 as a novel therapeutic target

2024/03/19 by Izuma Nakayama, Changsong Qi, Yang Chen +3 · 1 voice · 4 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience · #Barrier Structure and Function Studies #Cancer-related molecular mechanisms research #Pancreatic and Hepatic Oncology Research

paper · doi:10.1038/s41571-024-00874-2

crossref issued 2024/03/19 · crossref published 2024/03/19 · crossref published-online 2024/03/19 · openalex publication_date 2024/03/19 · crossref created 2024/03/19 · crossref deposited 2024/04/24 · crossref published-print 2024/05/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31 · crossref indexed 2026/07/31

Citations

• Claudins and the Modulation of Tight Junction Permeability
• Transcriptional regulation of claudin‐18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells
• Claudin-18 Is an Early-Stage Marker of Pancreatic Carcinogenesis
• Gastric cancer
• Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Cited by

• Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy
• Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases
• Structure and function of therapeutic antibodies approved by the US FDA in 2024
• Loss of Kmt2c/d promotes gastric cancer and confers vulnerability to mTORC1 and PD-1 inhibition

Discussions

• 🏫Mini Tutorial 1🏫 CLDN18.2 In normal gastric mucosa: part of tight junctions, not accessible In gastric cancer: becomes exposed -> targetable doi.org/10.1038/s41571-024-00874-2 [bsky, 3 points, 2 comments]